Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 14/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 14/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.55 |
| ▸ | VNN1 | O95497 | 5/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16626820 | 0.92 | VNN1 (0.64) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL18742534 | 0.90 | HDAC3 (0.65) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL18742411 | 0.90 | HDAC3 (0.65) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL18712282 | 0.89 | HDAC3 (0.65) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL16677936 | 0.87 | HDAC6 (0.67) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL16677935 | 0.87 | HDAC3 (0.55) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL17832599 | 0.86 | HDAC1 (0.62) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL16644384 | 0.85 | HDAC3 (0.66) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL16644404 | 0.84 | HDAC3 (0.69) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL16644382 | 0.84 | HDAC3 (0.70) | HDAC3HDAC1HDAC2HDAC6VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055299-B1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS INC (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3055299-B1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS INC (US) | 2021-01-06 | — | — | EP | disclosed |
| US-9833466-B2 | Treatment of leukemia with histone deacetylase inhibitors | ACETYLON PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160279128-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160279128-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2016-09-29 | — | — | US | disclosed |
| EP-3055299-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | Acetylon Pharmaceuticals, Inc. (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160137630-A1 | INDUCTION OF GATA2 BY HDAC1 AND HDAC2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2016-05-19 | — | — | US | disclosed |
| US-9278963-B2 | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors | ACETYLON PHARMACEUTICALS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278963-B2 | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors | ACETYLON PHARMACEUTICALS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20160030458-A1 | TREATMENT OF LEUKEMIA WITH HISTONE DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS INC. | 2016-02-04 | — | — | US | disclosed |
| WO-2015054474-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150105384-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105384-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| WO-2015054474-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137630-A1 | INDUCTION OF GATA2 BY HDAC1 AND HDAC2 INHIBITORS | GATAD2B, GATAD2A, HDAC2 | HDAC3 22/4885HDAC1 4/4885HDAC2 3/4885 |
| US-20160279128-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | HDAC3 11/4885HDAC1 1/4885HDAC2 3/4885 |
| US-20150105384-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | HDAC3 11/4885HDAC1 1/4885HDAC2 3/4885 |
| US-20160030458-A1 | TREATMENT OF LEUKEMIA WITH HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC4, HDAC2 | HDAC3 8/4885HDAC1 1/4885HDAC2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.